Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806234 · ClinicalTrials.gov registry record · Phase 4
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
A Phase 4 study of Psychotic Disorders, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 127
- Enrollment target
- 4
- Study locations
NCT00806234: Completed Phase 4 study of Psychotic Disorders, sponsored by Johns Hopkins University.
NCT00806234 is a Phase 4 study of Psychotic Disorders that has completed, run by Johns Hopkins University. The registered enrollment target is 127 participants, below the 250-participant average among 22 other Psychotic Disorders trials with a reported enrollment target (49% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00806234, a Phase 4 study of Psychotic Disorders, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 127 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Aripiprazole or Perphenazine
- DRUG Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Study Locations (4)
Maryland
- University of Maryland - Baltimore
- Johns Hopkins Hospital - Baltimore
New York
- The Zucker Hillside Hospital - Glen Oaks
North Carolina
- University of North Carolina, Division of Child and Adolescent Psychiatry - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806234
The ClinicalTrials.gov registry entry for NCT00806234 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 250-participant average among 22 other Psychotic Disorders trials with a reported enrollment target (49% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psychotic Disorders appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.
NCT00806234 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Maryland, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00806234 about?
NCT00806234 is a clinical study titled "Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics". This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
What is the current status of trial NCT00806234?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2009-01. Estimated completion is 2014-03.
What conditions does trial NCT00806234 study?
This clinical trial studies the following conditions: Psychotic Disorders.
What interventions are being tested in trial NCT00806234?
The interventions under investigation include: Metformin (DRUG), Aripiprazole or Perphenazine (DRUG), Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00806234?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00806234 being conducted?
This trial has 4 study locations across Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychotic Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Antipsychotic Discontinuation in Alzheimer's Disease
COMPLETED · Phase 4
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
-
A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
RECRUITING · NA
-
Racial Disparities in the Expression of Paranoia
RECRUITING · NA
-
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
RECRUITING · NA
-
A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.